How have SABSW shares performed in 2024?

SAB Biotherapeutics' stock was trading at $0.0302 at the start of the year. Since then, SABSW shares have increased by 0.7% and is now trading at $0.0304. View the best growth stocks for 2024 here .

Are investors shorting SAB Biotherapeutics?

SAB Biotherapeutics saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 100 shares, a drop of 97.9% from the March 15th total of 4,700 shares. Based on an average daily volume of 14,200 shares, the short-interest ratio is currently 0.0 days. View SAB Biotherapeutics' Short Interest .

How do I buy shares of SAB Biotherapeutics?

Shares of SABSW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SABSW

SAB Biotherapeutics (SABSW) Stock Price, News & Analysis

→ Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad)

Free SABSW Stock Alerts

$0.03

0.00 (0.00%)

(As of 04/26/2024 ET)

Compare

Today's Range: $0.03
▼
$0.03
50-Day Range: $0.02
▼
$0.04
52-Week Range: $0.02
▼
$0.20

Volume: N/A
Average Volume: 22,055 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials SEC Filings Short Interest Social Media

Get SAB Biotherapeutics alerts:

Ad Weiss Ratings

Protect Yourself While There’s Still Time …

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.

SABSW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SABSW Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive SABSW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:SABSW
CUSIP: N/A
CIK: 1833214
Web: www.sabbiotherapeutics.com
Phone: 605-679-6980
Fax: N/A
Employees: 57
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $-11,221,976.00
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Samuel J. Reich (Age 49)
CEO & Executive Chairman
Comp: $363.2k
Dr. Eddie Joe Sullivan Ph.D. (Age 57)
Co-Founder, President & Director
Comp: $402.56k
Ms. Christine E. Hamilton M.B.A. (Age 68)
Co-Founder & Independent Director
Comp: $25k
Mr. Michael George King Jr. (Age 63)
EVP & CFO
Comp: $60.58k
Dr. Christoph Bausch M.B.A. (Age 53)
Ph.D., Executive VP & COO
Comp: $443.2k
Dr. Alexandra Kropotova M.B.A. (Age 51)
M.D., Executive VP & Chief Medical Officer
Comp: $774.45k
Dr. Edward D. Hamilton D.V.M.
Co-Founder & Board Observer
Dr. Carlos N. Carillo Ph.D.
Senior Vice President of Regulatory Affairs

Key Competitors

View All Competitors

SABSW Stock Analysis - Frequently Asked Questions

How have SABSW shares performed in 2024?: SAB Biotherapeutics' stock was trading at $0.0302 at the start of the year. Since then, SABSW shares have increased by 0.7% and is now trading at $0.0304.
View the best growth stocks for 2024 here.
Are investors shorting SAB Biotherapeutics?: SAB Biotherapeutics saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 100 shares, a drop of 97.9% from the March 15th total of 4,700 shares. Based on an average daily volume of 14,200 shares, the short-interest ratio is currently 0.0 days.
View SAB Biotherapeutics' Short Interest.
How do I buy shares of SAB Biotherapeutics?: Shares of SABSW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SABSW) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial